Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells $1,091,750.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the completion of the transaction, the insider owned 15,805 shares of the company’s stock, valued at approximately $313,729.25. This represents a 77.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 1.4%

NASDAQ IMNM opened at $21.49 on Thursday. The stock has a market cap of $2.43 billion, a P/E ratio of -9.03 and a beta of 2.07. The company’s 50-day simple moving average is $20.96 and its 200 day simple moving average is $21.76. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

Hedge funds have recently added to or reduced their stakes in the stock. Creative Planning raised its stake in shares of Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after purchasing an additional 935 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after purchasing an additional 1,442 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its position in Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after purchasing an additional 1,970 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on IMNM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Craig Hallum lifted their price objective on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Truist Financial lifted their price target on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Finally, Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research note on Friday, June 12th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.